Summary of Study ST001074

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000719. The data can be accessed directly via it's Project DOI: 10.21228/M8R38S This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST001074
Study TitleOpen source discovery of starting points for next generation chemoprotective antimalarial drugs (Biofocus 1)
Study TypeDrug Exposure
Study SummaryMetabolic examination/confirmation of resistance mutations observed in study
Pennsylvania State University
Last NameOwen
First NameEdward
AddressW-122 Millennium Science Complex, Pollock Road, University Park, PA 16802
Phone(814) 867-3527
Submit Date2018-02-15
Analysis Type DetailLC-MS
Release Date2018-10-16
Release Version1
Edward Owen Edward Owen application/zip

Select appropriate tab below to view additional metadata details:


Treatment ID:TR001132
Treatment Summary:Infected Red Blood cells were exposed to Antimalarial Compounds, associated with sample names
Treatment Protocol Filename:Metabolite_Extraction_for_LCMS_2017_Llinas.pdf
Treatment:Drug Treatment
Treatment Compound:MMV1432165, MMV1451822, MMV1068987, MMV1490405, MMV1490397, MMV1449124, MMV1432711, MMV1454442, MMV1010248, MMV1319550, MMV1427995, MMV1431916, MMV011772
Treatment Route:Addition to media
Treatment Dose:10xIC50
Treatment Dosevolume:10xIC50
Treatment Doseduration:2.5 hours
Treatment Vehicle:Stocks kept in either DMSO or Water
Cell Storage:Temperature/Gas Mixture controlled incubator
Cell Growth Container:6-well plate
Cell Growth Config:5 mL per well, each with 1x10^8 cells
Cell Media:RPMI 1640 w/ Albumax, Gentamycin, Hypoxanthine, HEPES, Sodium Bicarbonate
Cell Harvesting:PBS Wash followed by 90% methanol extraction